440 related articles for article (PubMed ID: 29017159)
1. Picrasidine I from Picrasma Quassioides Suppresses Osteoclastogenesis via Inhibition of RANKL Induced Signaling Pathways and Attenuation of ROS Production.
Kong L; Wang B; Yang X; Guo H; Zhang K; Zhu Z; Liu J; Hao D
Cell Physiol Biochem; 2017; 43(4):1425-1435. PubMed ID: 29017159
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Aronia melanocarpa 'Viking' Extracts in Attenuating RANKL-Induced Osteoclastic Differentiation by Inhibiting ROS Generation and c-FOS/NFATc1 Signaling.
Ghosh M; Kim IS; Lee YM; Hong SM; Lee TH; Lim JH; Debnath T; Lim BO
Molecules; 2018 Mar; 23(3):. PubMed ID: 29518052
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
5. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
6. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
8. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
9. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
[TBL] [Abstract][Full Text] [Related]
10. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
11. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
12. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling.
Thummuri D; Jeengar MK; Shrivastava S; Nemani H; Ramavat RN; Chaudhari P; Naidu VG
Pharmacol Res; 2015 Sep; 99():63-73. PubMed ID: 26022736
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
15. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.
Nikhil K; Sharan S; Roy P
Pharmacol Rep; 2015 Dec; 67(6):1264-72. PubMed ID: 26481551
[TBL] [Abstract][Full Text] [Related]
16. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
17. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
[TBL] [Abstract][Full Text] [Related]
18. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
19. The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
Abdallah BM; Ali EM; Elsawy H; Badr GM; Abdel-Moneim AM; Alzahrani AM
Biomed Res Int; 2019; 2019():9395146. PubMed ID: 31976330
[TBL] [Abstract][Full Text] [Related]
20. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
